Brokerages Anticipate Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) Will Post Quarterly Sales of $4.80 Million

Equities research analysts expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT – Get Rating) to announce sales of $4.80 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Clarus Therapeutics’ earnings. The lowest sales estimate is $4.40 million and the highest is $5.20 million. The company is expected to issue its […]

Related Keywords

,Schonfeld Strategic Advisors ,Powell Investment Advisors ,Clarus Therapeutics Company Profile Get Rating ,Zacks Investment Research ,Verition Fund Management ,Blue Water Acquisition Corp ,Citadel Advisors ,Clarus Therapeutics Holdings Inc ,Clarus Therapeutics Inc ,Get Rating ,Clarus Therapeutic ,Clarus Therapeutics ,Investment Research ,Strategic Advisors ,Investment Advisors ,Therapeutics Company Profile ,Therapeutics Inc ,Nasdaq Crxt ,Crxt ,Medical ,Ratings ,Consensus ,